GVHD outcomes and survival probabilities for ID-PTCy–treated patients. (A-B) Cumulative incidences of (A) all aGVHD and grade II-IV aGVHD and (B) all cGVHD and cGVHD requiring systemic therapy. (C) Prophylactic and therapeutic systemic immunosuppression use for GVHD in the first posttransplant year. Patients with graft failure were excluded. Patients were counted as being on immunosuppression if alive and still taking immunosuppression on the last day of each month. The number of patients in each group at each time point are shown. (D-E) Cumulative incidences of (D) relapse and (E) nonrelapse mortality. (F-I) Kaplan-Meier estimates of (F) disease-free survival, (G) overall survival, (H) overall survival stratified by the DRI, and (I) GVHD-free, relapse-free survival (GRFS). CI, confidence interval.